P53 Mediates Vast Gene Expression Changes That Contribute to Poor Chemotherapeutic Response in a Mouse Model of Breast Cancer  Crystal Tonnessen-Murray,

Slides:



Advertisements
Similar presentations
Figure 1. Gene expression analysis
Advertisements

M. Fu, G. Huang, Z. Zhang, J. Liu, Z. Zhang, Z. Huang, B. Yu, F. Meng 
Volume 44, Issue 1, Pages (January 2016)
Volume 2, Issue 2, Pages (February 2016)
Differential Expression of Circular RNAs in Glioblastoma Multiforme and Its Correlation with Prognosis  Junle Zhu, Jingliang Ye, Lei Zhang, Lili Xia,
Circulating Exosomal miR-17-5p and miR-92a-3p Predict Pathologic Stage and Grade of Colorectal Cancer  Fangfang Fu, Weiqin Jiang, Linfu Zhou, Zhi Chen 
Volume 2, Issue 3, Pages (March 2016)
Kenneth G. Geles, Wenyan Zhong, Siobhan K
Volume 17, Issue 12, Pages (December 2016)
Volume 21, Issue 13, Pages (December 2017)
Volume 63, Issue 1, Pages (July 2016)
Volume 2, Issue 4, Pages (April 2008)
Volume 16, Issue 12, Pages (September 2016)
Volume 45, Issue 1, Pages (July 2016)
Mutant IDH1 Promotes Glioma Formation In Vivo
Volume 33, Issue 1, Pages (July 2010)
Volume 11, Issue 2, Pages (August 2012)
Unmasking Transcriptional Heterogeneity in Senescent Cells
Volume 58, Issue 2, Pages (April 2015)
Volume 8, Issue 4, Pages (April 2011)
Brachyury-YAP Regulatory Axis Drives Stemness and Growth in Cancer
Learning More from Microarrays: Insights from Modules and Networks
Regulation of Mammary Luminal Cell Fate and Tumorigenesis by p38α
Notch Activation as a Driver of Osteogenic Sarcoma
Revealing Global Regulatory Perturbations across Human Cancers
Volume 5, Issue 1, Pages e4 (July 2017)
Volume 26, Issue 4, Pages (October 2014)
Volume 23, Issue 4, Pages (April 2018)
Temporal Control of Plant Organ Growth by TCP Transcription Factors
Transcriptional Landscape of Cardiomyocyte Maturation
Reduction of Inflammatory and Cardiovascular Proteins in the Blood of Patients with Psoriasis: Differential Responses between Tofacitinib and Etanercept.
Genomic characterization of the inflammatory response initiated by surgical intervention and the effect of perioperative cyclooxygenase 2 blockade  Keith.
Volume 33, Issue 4, Pages e6 (April 2018)
Volume 21, Issue 6, Pages (June 2012)
Distinctive pro-inflammatory gene signatures induced in articular chondrocytes by oncostatin M and IL-6 are regulated by Suppressor of Cytokine Signaling-3 
Volume 16, Issue 12, Pages (September 2016)
Volume 1, Issue 3, Pages (September 2013)
Volume 22, Issue 3, Pages (January 2018)
Volume 10, Issue 1, Pages (January 2018)
Volume 23, Issue 7, Pages (May 2018)
Volume 19, Issue 4, Pages (April 2014)
Revealing Global Regulatory Perturbations across Human Cancers
Volume 22, Issue 3, Pages (March 2012)
Volume 22, Issue 3, Pages (January 2018)
The BRD4 bromodomain is critical for expression of SASP genes.
Volume 22, Issue 3, Pages (September 2012)
Volume 89, Issue 6, Pages (March 2016)
Volume 54, Issue 5, Pages (June 2014)
Volume 9, Pages (November 2018)
Volume 9, Issue 4, Pages (November 2014)
Volume 35, Issue 2, Pages (August 2011)
Volume 25, Issue 6, Pages (June 2013)
Volume 8, Issue 4, Pages (April 2011)
Down-regulation of LATS1 promotes the formation of tumors enriched in basal-like features. Down-regulation of LATS1 promotes the formation of tumors enriched.
Haploinsufficiency at the Nkx3.1 locus
Volume 4, Issue 6, Pages (June 2015)
AZA treatment induces a distinct gene-expression pattern in stromal cells. AZA treatment induces a distinct gene-expression pattern in stromal cells. (A-C)
Volume 15, Issue 12, Pages (June 2016)
Volume 5, Issue 1, Pages e4 (July 2017)
Rational Design of Therapeutic siRNAs: Minimizing Off-targeting Potential to Improve the Safety of RNAi Therapy for Huntington's Disease  Ryan L Boudreau,
Volume 29, Issue 3, Pages (March 2016)
Maria S. Robles, Sean J. Humphrey, Matthias Mann  Cell Metabolism 
Volume 17, Issue 3, Pages (October 2016)
Reanalysis of an existing experiment using ADAGE
Volume 2, Issue 3, Pages (March 2016)
Volume 58, Issue 2, Pages (April 2015)
Genome-wide Functional Analysis Reveals Factors Needed at the Transition Steps of Induced Reprogramming  Chao-Shun Yang, Kung-Yen Chang, Tariq M. Rana 
DNA Damage-Induced Transcription of Transposable Elements and Long Non-coding RNAs in Arabidopsis Is Rare and ATM-Dependent  Zhenxing Wang, Rainer Schwacke,
Transcriptome profiling of PD-L1 antibody–treated macrophages showed inflammatory phenotype, increased survival and proliferation, and decreased apoptosis.
Molecular Therapy - Nucleic Acids
Presentation transcript:

p53 Mediates Vast Gene Expression Changes That Contribute to Poor Chemotherapeutic Response in a Mouse Model of Breast Cancer  Crystal Tonnessen-Murray, Nathan A. Ungerleider, Sonia G. Rao, Amanda R. Wasylishen, Wesley D. Frey, James G. Jackson  Translational Oncology  Volume 11, Issue 4, Pages 930-940 (August 2018) DOI: 10.1016/j.tranon.2018.05.003 Copyright © 2018 BAYLOR COLLEGE OF MEDICINE Terms and Conditions

Figure 1 p53 mediates the vast majority of gene expression changes in mammary tumors of mice treated with doxorubicin. MMTV-Wnt1 transgenic mice with mammary tumors that were Trp53+/+, Trp53−/−, or Cdkn1a−/− were untreated and harvested (Ctl), or treated with 4 mg/kg doxorubicin IP for 5 consecutive days and then harvested 24 hours following the final treatment (Doxo). (A) After RNA sequencing, scatter plots of differential gene expression in doxorubicin-treated (doxo) versus untreated control (Ctl) were generated for each genotype. Genes significantly changed (PPEE<.05) are represented by a blue point. (B) Heat maps corresponding to genotypes in the scatter plots of (A) were generated for control and doxorubicin-treated (indicated by +) tumors using the union of every differentially expressed gene for each genotype. (C) Bar chart of the total number of significantly regulated protein-coding genes (FDR<0.05) for Trp53+/+, Cdkn1a−/−, or Trp53−/− cohorts. (D). Venn diagram depicting total numbers of significantly regulated (FDR<0.05) protein-coding genes for each cohort analyzed and the numbers of commonly regulated genes. (E) Volcano plot showing FDR(PPEE) on the Y-axis and fold change on the X-axis for genes modulated after doxorubicin treatment in Trp53+/+ tumors. Those genes not significantly regulated in Cdkn1a-null tumors are shown in pink. Translational Oncology 2018 11, 930-940DOI: (10.1016/j.tranon.2018.05.003) Copyright © 2018 BAYLOR COLLEGE OF MEDICINE Terms and Conditions

Figure 2 Pathways identified by analysis of doxorubicin-induced gene expression include the p53 pathway and cell cycle. (A) Schematic of top nine upregulated p53 pathway members in each genotype that were identified by IPA as being regulated downstream of p53. Fold change is indicated by color bar. (B) GSEA using KEGG gene lists was performed on RNA-seq data, and running enrichment scores for Trp53-null (yellow line), Cdkn1a-null (blue line), and Trp53WT (orange line) were plotted. Shown under the enrichment score plots are corresponding ranking of genes in the KEGG p53 pathway among ~16,000 genes analyzed. Genes stacked to the left are positively correlated and those to the right negatively correlated with doxorubicin-treated samples. (C) GSEA using the REACTOME cell cycle gene sets for doxorubicin-treated versus untreated tumors for the same genotypes as in B. Translational Oncology 2018 11, 930-940DOI: (10.1016/j.tranon.2018.05.003) Copyright © 2018 BAYLOR COLLEGE OF MEDICINE Terms and Conditions

Figure 3 Gene expression patterns differ in Cdkn1a-null tumors that respond to doxorubicin with arrest or proliferation. (A) Heat map of untreated Cdkn1a-null tumors compared to treated tumors. Those noted as “−” were untreated; those noted as “a” arrested following treatment; and those noted as “p” continued to proliferate after treatment, transiting the cell cycle, consistent with more cell death and a superior response. (B). Venn diagrams showing number of statistically significant (PPEE<.05) gene expression changes after doxorubicin treatment that were shared in the comparisons of untreated tumors to “arresters” and to “proliferators” and in the combination of "arresters" and “proliferators” (Cdkn1a−/−). (C) GSEA using REACTOME cell cycle gene sets for gene expression comparisons of untreated to “arresters” and untreated to “proliferators.” (D) Heat map of gene expression in treated Cdkn1a-null tumors that arrested and treated tumors that proliferated. (E) Scatter plot of differentially expressed genes in doxorubicin-treated Cdkn1a-null tumors that arrested (X-axis) and proliferated (Y-axis). (F) GSEA for REACTOME cell cycle gene sets using gene expression comparison of arresters to proliferators as made in D and E. Translational Oncology 2018 11, 930-940DOI: (10.1016/j.tranon.2018.05.003) Copyright © 2018 BAYLOR COLLEGE OF MEDICINE Terms and Conditions

Figure 4 Senescence phenotype is induced by doxorubicin treatment in Trp53 wild-type tumors. (A) Heat map of the genes and their expression (color bar ranges from -2.2 to 8.3) from each genotype whose products were identified by IPA for upstream regulation by Cdkn2a. (B) GSEA using the KEGG Lysosome gene set was performed on doxorubicin-treated versus untreated tumors for Trp53WT, Trp53-null, and Cdkn1a-null genotypes. (C) GSEA using KEGG Lysosome gene set for gene expression comparisons of Cdkn1a-null untreated tumors to “arresters” and untreated to “proliferators.” (D) GSEA for KEGG Lysosome gene set using gene expression comparison between treated Cdkn1a null tumors that arrested compared to treated tumors that proliferated. Translational Oncology 2018 11, 930-940DOI: (10.1016/j.tranon.2018.05.003) Copyright © 2018 BAYLOR COLLEGE OF MEDICINE Terms and Conditions

Figure 5 Inflammatory genes are expressed in doxorubicin-treated mammary tumors. (A) GSEA using the KEGG Jak Stat and KEGG cytokine-cytokine receptor interaction gene sets was performed on doxorubicin-treated versus untreated tumors for Trp53WT, Trp53-null, and Cdkn1a-null genotypes. (B) CIBERSORT analysis was performed on gene expression data from Trp53WT, Trp53-null, and Cdkn1a-null genotypes, and relative enrichment of signatures for B cells, T cells, and macrophages was determined and graphed. t tests were performed for control (ctl) and doxorubicin-treated (doxo) tumors, * represents P < .05. (C) GSEA using KEGG Jak Stat and KEGG cytokine-cytokine receptor interaction gene sets was performed on doxorubicin-treated versus control tumors for gene expression comparisons of Cdkn1a-null untreated tumors to “arresters” and untreated to “proliferators.” (D) GSEA for KEGG Jak Stat and KEGG cytokine-cytokine gene sets was performed on treated Cdkn1a-null tumors that arrested compared to treated tumors that proliferated. Translational Oncology 2018 11, 930-940DOI: (10.1016/j.tranon.2018.05.003) Copyright © 2018 BAYLOR COLLEGE OF MEDICINE Terms and Conditions

Figure 6 Longitudinal expression of SASP senescence gene Cxcl5 over the course of treatment and relapse. C57Bl6/j mice were orthotopically transplanted with two different Trp53+/+, MMTV-Wnt1 tumors that express luciferase under the control of the Cxcl5 promoter region. Tumor volume was determined (solid lines, solid squares), and mice were imaged for luciferase expression (dashed line, open circles) regularly. Mice were left untreated (A) or were treated with five consecutive IP injections of 4 mg/kg doxorubicin (B) as indicated by arrowheads on the X-axis. Data are expressed graphically with tumor volume indicated by solid lines on the left Y-axis and luciferase activity normalized to tumor volume indicated by dashed lines on the right Y-axis. Translational Oncology 2018 11, 930-940DOI: (10.1016/j.tranon.2018.05.003) Copyright © 2018 BAYLOR COLLEGE OF MEDICINE Terms and Conditions